Boxers Shigetoshi Kotari, Hiromasa Urakawa die from brain injuries after Aug. 2 fights
Shigetoshi Kotari's death was announced by the World Boxing Council and World Boxing Organization on Aug. 8. The death of Hiromasa Urakawa was announced by the WBO on Aug. 9.
Kotari, 28, had lost consciousness, according to the WBC, after a 12-round match, a draw, against Yamato Hata for Hata's Oriental and Pacific Boxing Federation super featherweight title. Kotari was taken to the hospital and received emergency brain surgery for a subdural hematoma.
A subdural hematoma is a type of bleeding near the brain that can happen after a head injury, according to the Cleveland Clinic.
"Deeply sorry for this loss a ring accident which makes all of us go back to continue research to find ways to make boxing safer and implement prevention programs," Mauricio Sulaimán, the WBC's president, posted on social media. "Our deepest sympathy and condolences for his family and the boxing community in Japan."
Urakawa, 28, also needed brain surgery, a craniotomy, after a six-round loss to Yoji Saito at the same event, the BBC reported, citing the Japan Boxing Commission.
"We extend our deepest condolences to the families, friends, and the Japanese boxing community during this incredibly difficult time," the WBO posted.
The commission has since lowered OPBF title bouts from 12 rounds to 10.
This article originally appeared on USA TODAY: Shigetoshi Kotari, Hiromasa Urakawa die from boxing injuries
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Clozapine May Up Infection Risk in Schizophrenia
TOPLINE: Clozapine use was associated with a 25% higher risk for infections in patients with schizophrenia than the use of olanzapine, with a 45% higher risk in those aged 55 years or older, a large cohort study showed. METHODOLOGY: The population-based cohort study included electronic health record data from the Hong Kong Hospital Authority for more than 11,051 adults with schizophrenia. Participants had used clozapine (n = 1450; mean age, 41 years; 52% women) or olanzapine (n = 9601; mean age, 45 years; 55% women) continuously for 90 or more days and had previously used at least two other antipsychotic medications, representing a cohort with treatment resistance. The primary outcome was occurrence of any infectious disease, with subtypes analyzed as secondary outcomes. Medication was initiated from 2004 to 2023, with 2002-2003 as a wash-out period. Mean follow-up periods for clozapine and olanzapine users were about 6.9 years and 5 years, respectively. TAKEAWAY: Overall, 3551 cases of infections were observed during the study. Clozapine use was associated with a significantly greater risk for infection than olanzapine use (weighted hazard ratio [HR], 1.25; P < .0001). Risk for infection from use of clozapine vs olanzapine increased with age: 18-44 years (weighted HR, 1.24; P = .002), 44-54 years (weighted HR, 1.41; P = .001), and 55 years or older (weighted HR, 1.45; P = .002). Risk for upper and lower respiratory tract infections was also significantly higher with use of clozapine vs olanzapine (weighted HRs, 1.50 and 1.71, respectively; P < .0001 for both) as was the risk for gastrointestinal infections (weighted HR, 1.90; P = .0001). Although men and women both had significantly greater infection risk with use of clozapine vs olanzapine, the rate was greater in men (weighted HRs, 1.32 and 1.18, respectively). IN PRACTICE: The investigators noted that although there have been calls to relax current requirements for regular hematological monitoring when using clozapine, their findings 'underscore the importance of regular follow-up to identify early and manage infections, which possibly arise because of a weakened immune system.' Authors of an accompanying editorial noted that patients receiving higher doses might be at even greater risk for adverse events. 'An intermediate balance of personalized dosing designed to limit clozapine-induced inflammation and regular blood testing and physical monitoring…could offer a safe and less invasive compromise to maximize the number of patients receiving clozapine treatment,' the editorial authors wrote. SOURCE: The study was led by Yuqi Hu, the University of Hong Kong, Hong Kong. The editorial was led by Scott R. Clark, University of Adelaide, Adelaide, Australia. Both were published online on July 28 in The Lancet Psychiatry. LIMITATIONS: The study was limited by its observational design, which may have introduced selection bias, and by the absence of key covariates, including socioeconomic status and lifestyle factors. It also lacked laboratory data on drug levels and immune function and only captured infections requiring secondary or tertiary care. Additional constraints included unmeasured anticholinergic effects, a predominantly Chinese cohort that limited generalizability, and not including patients with lived experience. DISCLOSURES: The study was partially supported by the Laboratory of Data Discovery for Health funded by AIR@InnoHK. Some of the study investigators and editorialists reported having financial, advisory, or employment ties with various sources, including pharmaceutical companies. Full details are provided in the original articles. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
Italian athlete dies at World Games in China
Italian orienteering athlete Mattia Debertolis died on Tuesday at the World Games in Chengdu, China after collapsing during competition, organisers said. Debertolis, 29, was found unconscious during an orienteering event on August 8 and died four days later, said a joint statement from World Games organisers and the International Orienteering Federation (IOF). The World Games is a multisport event held every four years for disciplines not included in the Olympics. "Despite receiving immediate expert medical care at one of China's leading medical institutions, he passed away," the statement said. It did not provide details on the cause of death. Orienteering sees athletes navigate an unmarked course with a map and compass, punching in at designated spots along the route, in the quickest time. The event, held approximately 50 kilometres (30 miles) outside of central Chengdu, took place in intense heat and humidity, with temperatures above 30 degrees. Debertolis was taking part in the final of the men's middle-distance event when he collapsed. The winner, Switzerland's Riccardo Rancan, completed the course in 45 minutes and 22 seconds. Debertolis was listed as "Did Not Finish" in official results, along with 11 other athletes. He was ranked 137th in the men's Orienteering World Rankings and had been competing since 2014, according to the IOF website. He participated in several World Championships and World Cups as part of the Italian team. This is the 12th edition of the World Games and it runs until August 17. World Games organisers and the IOF will "continue to support the family of Mattia Debertolis and the orienteering community in every possible way", the joint statement said. sam/reb/pst
Yahoo
3 hours ago
- Yahoo
Al-Nassr open talks to sign Bayern Munich's Kingsley Coman
As they have done in the previous two summer windows, the Saudi Pro League are looking to attract some of the stars of the European game. According to a report from , Bayern Munich's Kingsley Coman (27) has emerged as the latest target. Al-Nassr are the club interested in signing the France international, Romano understands. The Saudi side have already had a busy summer, with a Euro-centric focus once again in their recruitment drive. João Félix has arrived for big money from Chelsea, whilst a deal is set to be wrapped up to bring Iñigo Martínez to the club. They aren't done there. Al-Nassr are also in talks with Bayern Munich about a deal to bring Coman to the club, too. There are currently club-to-club talks over the winger, with the Frenchman having been identified as a top target. Talks between the player's camp and Al-Nassr are also ongoing. His contract with the reigning Bundesliga champions runs until 2027. GFFN | Luke Entwistle
